X-linked MeCP2 is first reported to be a new target for treating Parkinson's disease

X-linked methyl-CpG binding protein 2 plays important role in the regulation of neuronal development, proliferation and maturation, and synaptic regeneration and apoptosis. Overexpression of X-linked methyl-CpG binding protein 2 in SH-SY5Y cells can reduce cell apoptosis induced by 6-hydroxydopamine and increased tyrosine hydroxylase expression. But the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson's disease remains unknown. Prof. Xianhou Yuan and team from Zhongnan Hospital of Wuhan University used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson's disease. The researchers found that overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings, published in the Neural Regeneration Research (Vol. 8, No. 21, 2013), suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson's disease.

Article: " Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease? " by Teng Xie1, Jie Zhang1, Xianhou Yuan1, Jing Yang2, Wei Ding1, Xin Huang1, Yong Wu1 (1 Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China; 2 Department of Pharmacology, Wuhan University School of Medicine, Wuhan 430071, Hubei Province, China)

Xie T, Zhang J, Yuan XH, Yang J, Ding W, Huang X, Wu Y. Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease? Neural Regen Res. 2013;8(21):1948-1957.

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
http://www.nrronline.org/

Full text: http://www.sjzsyj.org:8080/Jweb_sjzs/CN/article/downloadArticleFile.do?attachType=PDF&id=665

---

---